Growth velocity and related factors during GnRH analog therapy for idiopathic central precocious puberty
10.3760/cma.j.issn.1008-6706.2020.13.012
- VernacularTitle:促性腺激素释放激素类似物治疗中枢性性早熟患儿生长速率及相关因素分析
- Author:
Miao LI
1
;
Deyun LIU
Author Information
1. 安徽医科大学第二附属医院儿科，合肥 230000
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(13):1586-1590
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the growth velocity and influencing factors of gonadotropin-releasing hormone analog (GnRHa) in the treatment of idiopathic central precocious puberty (ICPP).Methods:A retrospective cohort study was conducted in 50 girls diagnosed with ICPP who received GnRHa treatment for 2 years in the Second Affiliated Hospital of Anhui Medical University from May 2016 to June 2017.The growth velocity, the time and frequency of the occurrence of deceleration were observed, and the growth velocity-related factors were analyzed.Results:The growth rate of children with ICPP before GnRHa treatment (GV 0) was (7.61±1.69)cm/year, and the growth velocity of children after GnRHa treatment for 1 year(GV 1) and 2 years(GV 2) were (6.72±1.93)cm/year and (5.65±1.44)cm/year, respectively, the differences was statistically significant(GV 0>GV 1>GV 2, F=38.261, P<0.01). The growth velocity decreased gradually after treatment.When the correlation analysis of growth velocity was carried out, it was found that the early bone age (BA-CA) was negatively correlated with the first year growth velocity (GV 1). However, bone age, basal value of LH and peak value of LH were negatively correlated with the growth velocity of the second year, with correlation coefficients of -0.283, -0.283 and -0.378 (all P<0.05). The peak value of LH ( P<0.01) was significantly correlated with the growth velocity of the second year (GV 2), but GV 2 was not correlated with the age of first diagnosis, height, weight, ovarian volume and other factors. Conclusion:GnRHa in the treatment of ICPP patients, the growth velocity gradually decreased, while the patients with higher LH, older bone, are more likely to have excessive growth deceleration in the second year of treatment.
